News Agency
The Times

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

  • Written by PR Newswire
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and...

Read more: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel...

Why Businesses Rely On Accountants in Melbourne For Financial Success

Managing finances effectively is essential for individuals, business owners, investors, and growing organisations. Financial decisions influence profitability, compliance, cash flow, and long-term wealth creation, making professional financial guidance an important part of successful planning. Many individuals and businesses choose to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion